Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer
Wolf, Gregory T., Fee Jr, Willard E., Dolan, Robert W., Moyer, Jeffrey S., Kaplan, Michael J., Spring, Paul M., Suen, James, Kenady, Daniel E., Newman, Jason G., Carroll, William R., Gillespie, M. Boyd, Freeman, Scott M., Baltzer, Lorraine, Kirkley, Terry D., Brandwein, Harvey J., Hadden, John W.
Published in Head & neck (01.12.2011)
Published in Head & neck (01.12.2011)
Get full text
Journal Article
Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic
Czystowska, Malgorzata, Szczepanski, Miroslaw J, Szajnik, Marta, Quadrini, Karen, Brandwein, Harvey, Hadden, John W, Whiteside, Theresa L
Published in Cancer Immunology, Immunotherapy (01.04.2011)
Published in Cancer Immunology, Immunotherapy (01.04.2011)
Get full text
Journal Article
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen
Berinstein, Neil L., Wolf, Gregory T., Naylor, Paul H., Baltzer, Lorraine, Egan, James E., Brandwein, Harvey J., Whiteside, Theresa L., Goldstein, Lynn C., El-Naggar, Adel, Badoual, Cecile, Fridman, Wolf-Herve, White, J. Michael, Hadden, John W.
Published in Cancer Immunology, Immunotherapy (01.06.2012)
Published in Cancer Immunology, Immunotherapy (01.06.2012)
Get full text
Journal Article
A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck
Freeman, Scott M, Franco, Jose Luis Barrera, Kenady, Daniel E, Baltzer, Lorraine, Roth, Zygmund, Brandwein, Harvey J, Hadden, John W
Published in American journal of clinical oncology (01.04.2011)
Published in American journal of clinical oncology (01.04.2011)
Get more information
Journal Article
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma
Whiteside, Theresa L., Butterfield, Lisa H., Naylor, Paul H., Egan, James E., Hadden, John W., Baltzer, Lorraine, Wolf, Gregory T., Berinstein, Neil L.
Published in Cancer Immunology, Immunotherapy (01.06.2012)
Published in Cancer Immunology, Immunotherapy (01.06.2012)
Get full text
Journal Article
Immunopharmacology of Thymosin alpha 1 and Cytokine Synergy
Naylor, Paul H, Quadrini, Karen, GARACI, ENRICO, Rasi, Guido, Hadden, John W
Published in Annals of the New York Academy of Sciences (01.09.2007)
Published in Annals of the New York Academy of Sciences (01.09.2007)
Get full text
Journal Article
IRX-2 increases the T cell-specific immune response to protein/peptide vaccines
Naylor, Paul H, Hernandez, Karla E, Nixon, April E, Brandwein, Harvey J, Haas, Gabriel P, Wang, Ching Y, Hadden, John W
Published in Vaccine (08.10.2010)
Published in Vaccine (08.10.2010)
Get full text
Journal Article
IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro
Egan, James E, Quadrini, Karen J, Santiago-Schwarz, Frances, Hadden, John W, Brandwein, Harvey J, Signorelli, Kathy L
Published in Journal of immunotherapy (1997) (01.09.2007)
Published in Journal of immunotherapy (1997) (01.09.2007)
Get more information
Journal Article
Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2
Meneses, Abelardo, Verastegui, Emma, Barrera, Jose L, de la Garza, Jaime, Hadden, John W
Published in International immunopharmacology (01.08.2003)
Published in International immunopharmacology (01.08.2003)
Get full text
Journal Article
Preclinical studies with IRX-2 and thymosin α1 in combination therapy
Naylor, Paul H., Hadden, John W.
Published in Annals of the New York Academy of Sciences (01.05.2010)
Published in Annals of the New York Academy of Sciences (01.05.2010)
Get full text
Journal Article